TG Therapeutics | TGTX - Selling And Administration Expenses


TG Therapeutics reported $62.32M in Selling and Administration Expenses for its fiscal quarter ending in June of 2026.





Selling And Administration Expenses Change Date
AbbVie USD 3.63B 54M Jun/2026
Alaunos Therapeutics USD 447K 138K Mar/2026
Amgen USD 1.72B 134M Jun/2026
Ardelyx USD 102.27M 26.35M Mar/2026
Arrowhead Research USD 46.63M 4.88M Jun/2026
Bayer EUR 3.96B 267M Jun/2026
Biogen USD 709.7M 155.4M Jun/2026
Corcept Therapeutics USD 156.9M 28.85M Jun/2026
Curis USD 2.96M 1.62M Mar/2026
Gilead Sciences USD 1.52B 70M Jun/2026
J&J USD 6.42B 381M Jun/2026
Karyopharm Therapeutics USD 10.42M 861K Mar/2026
Novartis USD 3.24B 101M Jun/2026
Novavax USD 25.53M 1.34M Dec/2025
PTC Therapeutics USD 73.89M 13.31M Mar/2026
Puma Biotechnology USD 16.82M 8.15M Sep/2024
Regeneron Pharmaceuticals USD 662.1M 14.4M Jun/2026
Roche Holding CHF 6.37B 908M Jun/2026
TG Therapeutics USD 62.32M 10.82M Jun/2026
Verastem USD 22.3M 2.14M Mar/2026
Vertex Pharmaceuticals USD 582.2M 88.5M Jun/2026